These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 8422000

  • 1. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
    van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW.
    Am J Cardiol; 1993 Jan 21; 71(3):21A-28A. PubMed ID: 8422000
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663
    [Abstract] [Full Text] [Related]

  • 3. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
    Kinugawa T, Ogino K, Kato M, Furuse Y, Shimoyama M, Mori M, Endo A, Kato T, Omodani H, Osaki S, Miyakoda H, Hisatome I, Shigemasa C.
    Gen Pharmacol; 1998 Jul 15; 31(1):93-9. PubMed ID: 9595286
    [Abstract] [Full Text] [Related]

  • 4. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D.
    Eur Heart J; 1995 Dec 15; 16 Suppl N():107-10. PubMed ID: 8682055
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
    Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD.
    Am J Cardiol; 1995 Dec 15; 76(17):1259-65. PubMed ID: 7503007
    [Abstract] [Full Text] [Related]

  • 8. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 9. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
    Lim PO, MacFadyen RJ, Struthers AD.
    Heart; 2000 Mar 26; 83(3):257-61. PubMed ID: 10677399
    [Abstract] [Full Text] [Related]

  • 10. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
    Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M.
    Circulation; 2000 Nov 07; 102(19):2325-8. PubMed ID: 11067783
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 07; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 07; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 14. [Classic treatment of chronic heart insufficiency. What if new?].
    Aumont MC, Agnola D, Juliard JM, Karrillon G.
    Arch Mal Coeur Vaiss; 1995 Apr 07; 88(4 Suppl):599-602. PubMed ID: 7487308
    [Abstract] [Full Text] [Related]

  • 15. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ.
    Am J Kidney Dis; 1987 Jul 07; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [Abstract] [Full Text] [Related]

  • 16. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
    Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M.
    J Nucl Med; 2002 Oct 07; 43(10):1279-85. PubMed ID: 12368364
    [Abstract] [Full Text] [Related]

  • 17. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 07; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 18. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C, Donker AJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1724-6. PubMed ID: 10494316
    [Abstract] [Full Text] [Related]

  • 19. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
    Christ M, Ludwig N, Maisch B.
    Herz; 2002 Mar 21; 27(2):135-49. PubMed ID: 12025459
    [Abstract] [Full Text] [Related]

  • 20. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.
    J Card Fail; 2004 Aug 21; 10(4):297-303. PubMed ID: 15309695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.